# A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

> **NCT02954692** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 112 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** INSULIN GLARGINE (U300)
- **DRUG:** metformin
- **DRUG:** sulfonylurea
- **DRUG:** meglitinides
- **DRUG:** thiazolidinediones
- **DRUG:** alpha-glucosidase inhibitors
- **DRUG:** GLP1 Receptor Agonist
- **DRUG:** Dipeptidyl peptidase-IV (DPP-IV) inhibitors
- **DRUG:** Sodium-glucose transport-2 (SGLT-2) inhibitors

## Key facts

- **NCT ID:** NCT02954692
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-30
- **Primary completion:** 2017-12-22
- **Final completion:** 2017-12-22
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02954692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02954692, "A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT02954692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*